# Soluble DNA Concentration in the Perfusate is a Predictor of Post-Transplant Renal Function in Hypothermic Perfused Kidney Allografts

Sergio Duarte PhD<sup>1</sup>, Anne-Marie Carpenter MD<sup>1</sup>, Matthew Willman BS<sup>1</sup>, Duncan Lewis BS<sup>1</sup>, Curtis Warren MPH<sup>1</sup>, Isabella Angeli-Pahim MD<sup>1</sup>, Werviston De Faria MD<sup>1</sup>, Georgios Vrakas MD, PhD<sup>1</sup>, Ashraf El Hinnawi MD<sup>1</sup>, Thiago Beduschi MD<sup>1</sup>, Narendra Battula MD<sup>2</sup>, Ali Zarrinpar MD, PhD<sup>\*1</sup>

<sup>1</sup>University of Florida College of Medicine, Department of Surgery, Division of Transplantation and Hepatobiliary Surgery, Gainesville, FL

<sup>2</sup>Oklahoma University College of Medicine, Department of Surgery, Division of Transplant Surgery, Oklahoma City, OK

\*Corresponding author: Ali Zarrinpar, 1329 SW 16th St, Gainesville, FL 32608, P: (352) 265-0606, F: (352) 265-0678, ali.zarrinpar@surgery.ufl.edu

Keywords: kidney transplant, renal transplant, renal allograft, cell-free DNA, biomarker, delayed graft function, transplant outcome, hypothermic machine perfusion

Electronic word count: 2572

Conflicts of interest: none

### Abstract

**Introduction**: Hypothermic machine perfusion (HMP) has greatly facilitated kidney allograft preservation. However, tissue damage still occurs during HMP, deleteriously affecting post-transplant graft function. Therefore, improved methods to assess organ quality and to predict post-transplant graft function and survival are needed. We propose that soluble DNA (sDNA) measured in HMP perfusate can used as a non-invasive biomarker for this purpose.

**Methods:** Perfusate samples of kidney grafts placed on HMP were collected after 5 minutes and at the conclusion of HMP. sDNA of nuclear origin within the perfusate was quantified by real-time polymerase chain reaction and correlated with HMP parameters and post-transplant clinical outcomes.

**Results:** Kidney grafts from 52 donors placed on HMP were studied. Perfusate sDNA concentration was significantly elevated in transplanted kidneys with delayed graft function. Grafts with higher concentrations of perfusate sDNA at 5min and at HMP conclusion also had reduced graft function in the initial post-transplant period, as measured by post-operative day 2, 3, and 4 creatinine reduction ratios (CRR). Standard pump parameters such as renal vascular resistance and renal vascular flow were poor indicators of early post-transplant graft function. **Conclusion:** sDNA concentration in HMP perfusate of kidney grafts can predict the quality of kidney graft preservation and indicate post-transplant renal function. This biomarker should be explored further to improve renal organ assessment and transplantation outcomes.

### Introduction

Advances in allograft preservation within the last century have transformed the field of solid organ transplantation. In renal transplantation, the widespread use of hypothermic machine perfusion (HMP) has become standard of care in kidney preservation, maintaining organ viability in the transition from donor to recipient and greatly reducing postoperative delayed graft function in the recipient compared to static cold storage (SCS).<sup>1,2,3</sup> Additionally, HMP allows for longer storage times compared to SCS,<sup>4</sup> providing the opportunity to continuously assess intrinsic graft attributes and levels of tissue damage that contribute to poor graft function, which is associated with recipient morbidity and mortality.<sup>5</sup> Allografts continue to accrue injury during the preservation period; as such the quality of the graft upon procurement will not be the same after 24 to 48 hours of preservation. Thus, demand is high for methods to assess graft quality repeatedly during the preservation period and to predict graft function after transplantation.

In renal allografts preserved with HMP, methods of predicting donor organ function have had marginal success in reliably predicting organ damage and subsequent graft function. Currently, the most widely used method relies on dynamic parameters measured by the perfusion machine, namely, vascular resistance and flow, where flow correlates positively with graft function and resistance correlates negatively.<sup>6</sup> However, the use of these indices to guide acceptance or rejection of donated kidneys has been criticized, as many allografts that may have been discarded on the basis of unacceptable pump parameters later demonstrate sufficient function after transplantation.<sup>7,8,9</sup>

To aid decision-making regarding donor organ acceptance, new avenues are being explored. Some have adopted a composite score assessing macroscopic appearance, flow, and urine output, when kidney grafts are subject to normothermic perfusion.<sup>10</sup> Additional studies have focused on measuring biomarkers in the HMP perfusate, such as lactate dehydrogenase, aspartate transaminase, glutathione-S-transferase, interleukin-18, and other surrogates for glucose metabolism, oxygen consumption, glycolytic activity, ATP depletion, and mitochondrial damage.<sup>11,12,13</sup> However, none of these dynamic values or biomarkers have demonstrated adequate power to predict post-transplant kidney function.<sup>14,15</sup> To date, a reliable method to directly measure renal allograft injury and predict postoperative renal function has not been established.

While no biomarker of machine-perfused donor organ injury and subsequent recipient allograft function has been validated for kidneys, some success has been achieved in lung transplantation. In a recent study, Kanou et al. measured the amount of cell-free DNA (herein referred to as soluble DNA or sDNA to avoid confusion with donor-derived cell-free DNA being quantified in recipient blood) in the perfusate of human donor lungs undergoing *ex vivo* HMP; they found that the concentration of sDNA was significantly higher in perfusates from lungs that developed severe primary graft dysfunction.<sup>16</sup> These findings are echoed in a pre-clinical renal allograft study performed by our group. We quantified perfusate sDNA within porcine kidneys undergoing HMP and found that the amount of sDNA measured was directly proportional to histologic features of tissue necrosis.<sup>17</sup> These findings served as the foundation for the study described herein.

In this study, we posit that sDNA measured within the HMP perfusate of human kidney allografts can be used as a non-invasive biomarker for organ integrity and as a result is able to predict post-transplant renal function.

### Methods

#### **Study Design**

This is a single-center, prospective cohort study approved by the Institutional Review Board at the University of Florida (IRB#202001674). All human kidneys preserved by HMP as standard-of-care between July 2021 and December 2022 were included. Kidneys intended for pediatric (<18 years) recipients, discarded kidneys that were not transplanted, kidneys that were pumped at another institution prior to arriving at our institution, and kidneys involved in multiorgan transplants were excluded. Fifty-two kidneys and recipients were included in this study.

HMP parameters measured and registered for this study were renal vascular resistance (RR) and flow (RF) at initiation, 2 hours, 4 hours (if applicable), and endpoint of perfusion. The primary endpoint of the study was delayed graft function (DGF), defined as the need for dialysis within the first 7 days after transplantation. Secondary endpoints were post-transplant clinical outcomes indicative of early graft function such as estimated glomerular filtration rate (eGFR), creatinine (Cr), and creatinine reduction ratio (CRR, defined in Equation 1), which were measured on postoperative days (POD) 1, 2, 3, and 4. We restricted our analysis of early graft function to the first 4 postoperative days at the end of which most of the study subjects are discharged at our institution; the clinical outcomes datasets and study N decreases for each subsequent time point. A schematic of the study methodology is depicted in Figure 1.

 $CRR = \frac{Creatinine \ Day \ X \ - \ Creatinine \ Pre \ Transplant}{Creatinine \ Day \ X}$ 

Equation 1. Creatinine Reduction Ratio

#### **Clinical Ex vivo Kidney Machine Perfusion Procedure**

Kidneys utilized during the study period underwent HMP using the LifePort Kidney Transporter 1.1 (Organ Recovery Systems, Itasca, IL), according to manufacturer instructions and as described in previous investigations.<sup>18,19</sup> UW Machine Perfusion solution was used as perfusate. Perfusate samples of the kidney grafts selected for HMP were collected after 5 minutes of perfusion and at the conclusion of HMP at graft handoff to the surgical team for implantation.

#### sDNA Extraction and PCR Quantification

The sDNA within each HMP perfusate sample was isolated using the QIAamp MinElute ccfDNA Mini Kit (QIAgen Group, Germantown, MD) according to manufacturer instructions. Briefly, 2mL perfusate was added to the proprietary magnetic bead suspension, which allows for binding of cell-free DNA to magnetic beads. The bound cell-free DNA was then eluted from the beads and purified using the QIAamp MinElute membrane. Purified cell-free DNA eluted from the membrane is the resulting soluble DNA (sDNA) sample. The nuclear-origin sDNA within the eluate was then quantified by real-time polymerase chain reaction (RT-PCR) using specific primer sequences for DNA of nuclear origin (customized oligonucleotide targeting GAPDH gene, Integrated DNA Technologies, Coralville, Iowa).

#### **Statistical Analysis**

Statistical analysis was performed using the R software package (V.4.1.3, The R Foundation for Statistical Computing). Non-parametric Spearman correlations were used to assess the relationships (direction and strength) between sDNA concentration and HMP

parameters, as well as between sDNA concentration and postoperative variables. Linear regression analysis was used to assess the effect of sDNA concentration on these outcomes.

### Results

#### Graft, Donor and Recipient characteristics

A total of 52 kidneys and 52 recipients were studied. Demographic characteristics of donors and recipients are reported in Table 1. The majority of donor allografts were obtained from male (60.8%) donors after brain death (75.5%). Donor kidneys had a mean 640±309 min of static preservation on ice prior to placement on HMP, a mean 477±256 min of HMP, and a mean 1127±405 min of total cold ischemia. There was a significant relationship only between perfusate sDNA concentration at HMP conclusion (hereafter referred to as handoff) and total cold ischemia time (Table 2;  $\rho$ =0.3049). There were five cases of DGF among the recipients within the study period.

#### Association between ex vivo perfusion variables and post-operative graft function.

In keeping with previous findings that standard means of measuring HMP donor organ integrity are poor predictors of post-transplant clinical measure of graft function, Table 3 presents the association of these variables with early postoperative Cr, eGFR, and CRR. There was no significant relationship between RF and any clinical measure of early post-transplant graft function. In contrast, we did observe a significant correlation between endpoint RR and Cr on all postoperative days up to day 4. Furthermore, neither RF or RR correlated significantly with CRR on any of the assessed postoperative days.

#### Association between KDPI and post-operative graft function

The Kidney Donor Profile Index (KDPI) is a cumulative percentile measure that characterizes the donor associated risk of post-transplant graft failure and aids transplant physicians in their decision to transplant a graft.<sup>20</sup> However, the impact of HMP on KDPI's association with early graft function is still unknown. When the KDPI was examined, we observed statistically significant correlations between KDPI and Cr, as well as eGFR on all postoperative days (Table 3). In contrast, there was no notable statistically significant relationship between KDPI and CRR as a measure of early post-operative graft function.

#### Perfusion parameters correlate with perfusate sDNA

Next, we investigated whether standard perfusion measures that are currently used to assess organ quality correlated with perfusate sDNA levels. To do so, we compared sDNA at five minutes and at handoff to RR and RF at the start of HMP, at 2-hour and 4-hour time points, and at the conclusion of HMP (Supplementary Table 1). Five-minute (5min) perfusate sDNA levels correlated positively with graft RF on the pump at 2 hours and 4 hours, while handoff sDNA correlated with 2-hour, 4-hour, and final RF (Supplementary Table 1, Supplementary Figure 1). There was a negative trend in the correlations between RR and sDNA at 5min and at handoff, although these were not significant.

#### Perfusate sDNA levels correlate with measures of early graft function.

We then turned our attention to assessing whether perfusate sDNA levels correlate with post-transplant function. There was a statistically significant correlation between 5min sDNA and post-transplant graft function, with higher 5min perfusate sDNA concentrations correlating with lower CRR on POD2 and POD4 (Supplementary Table 2, Supplementary Figure 2).

Importantly, grafts with higher concentration of perfusate sDNA at time of graft handoff had significantly reduced early post-transplant graft function (Table 4, Figure 2). Specifically, higher handoff sDNA concentrations correlated strongly with lower CRR on all postoperative days, lower POD3 eGFR, and higher POD3 and POD4 serum Cr levels.

#### sDNA levels predict delayed graft function

Finally, we examined the relationship between sDNA in HMP perfusate and the development of DGF postoperatively. There was a significantly higher level of handoff sDNA (p=0.018) and 5min sDNA (p=0.047) in the kidneys whose recipients ultimately exhibited DGF in comparison with the kidneys that did not exhibit DGF (Figure 3A, 3B). The receiver operating characteristics (ROC) curve for our cohort determined that sDNA concentration as a biomarker for DGF has a reliable prognostic performance with an area under the curve (AUC) of 0.816 (95% CI 0.68-0.96; p=0.021) in samples obtained at kidney handoff to surgeon, and an AUC of 0.771 (95% CI 0.58-0.96; p=0.048) in samples obtained at 5min of perfusion. Based on a Youden index/ROC curve analysis of the cohort, using 2.69 ng/ml of sDNA in the handoff perfusate as the threshold for the likelihood of post-transplant DGF yields 100% sensitivity (95% CI 0.57-1.00) and 64.7% specificity (95% CI 0.51- 0.76) (Figure 3C, 3D). In comparison, the ROC curves generated for KDPI, RR, and RF in predicting DGF were less reliable and were not statistically significant with this cohort (Figure 3E, 3F, 3G).

### Discussion

The utilization of kidney allografts is left to the discretion of transplant physicians. This can be a daunting task, as the recipient's health and quality of life is significantly affected by the outcome of this decision.<sup>21</sup> Several factors, such as KDPI, appearance, ischemia time, histologic

features of any biopsy, and dynamic values such as RR and RF produced during HMP, are used to inform the decision. However, there is no quantitative, noninvasive, repeatable biomarker of tissue damage correlating with postoperative renal function available to aid in the decisionmaking process. In this study, we propose sDNA measured in HMP perfusate of renal allografts as one such biomarker.

Soluble DNAs are cell-free, circulating, short fragments of DNA released from injured, necrotic, apoptotic, and other dying cells. Soluble DNA can be measured and characterized in plasma and is revolutionizing many medical fields such as oncology, maternal fetal medicine, and transplantation.<sup>22,23,24</sup> The measurement of DNA has become a useful practice in determining allograft integrity in the post-transplant setting.<sup>25</sup> Several studies have validated that donor-derived cell-free DNA can be quantified in the bloodstream of renal transplant recipients and used as a surrogate for graft injury.<sup>26,27,28</sup> As it has been shown to be a biomarker for graft damage in the recipient bloodstream, it is likely that measurement of soluble DNA in the perfusate during HMP could also provide insight as to graft damage prior to transplantation. This was very recently demonstrated in pulmonary allografts,<sup>16</sup> but has not been shown within human donor kidneys for which HMP is widely established as a clinical standard, until now.

Here, we confirm that sDNA is a reliable measure of early graft function in a posttransplant population. We demonstrate that sDNA within the HMP perfusate correlates with markers of renal function post-transplant. Specifically, higher 5-minute sDNA concentrations correspond with lower CRR on POD2 and POD4 (Supplementary Table 2, Supplementary Figure 2), and a higher level of sDNA at handoff significantly correlates with a lower CRR on all postoperative days (Table 4, Fig 2). The rate of creatinine clearance after transplantation is a more relevant assessment of short-term graft function than simple creatinine levels. CRR is an

accurate of measure of this rate. Additionally, CRR calculated on POD2 has previously been shown to predict long-term graft outcomes, specifically serum Cr at one year and at 5 years posttransplant.<sup>29,30,31</sup> In comparison, none of the commonly employed predictors of a graft's suitability (KDPI, RR, and RF) were significantly correlated with CRR on any postoperative day in this study (Table 3). We do note that higher KDPI was significantly correlated with lower eGFR in our study (Table 3), supporting its continued use to guide decisions regarding graft suitability in conjunction with other parameters such as sDNA concentration.

One finding within our study requires additional scrutiny, namely, the observation that renal flow is positively correlated with sDNA concentration, while renal resistance is negatively correlated (Supplementary Table 1, Supplementary Figure 1). While counterintuitive, one possible explanation for these results is that higher flow during HMP allows for greater exposure of damaged tissue to the HMP perfusate, allowing the nuclear-origin DNA to solubilize within the solution and thus be detected at higher concentration. This relationship between sDNA and pump parameters requires further investigation, but our findings nonetheless indicate that higher sDNA within HMP perfusate is associated with worse post-transplant outcomes, particularly lower eGFR and CRR (Supplementary Table 2, Supplementary Figure 2, Table 4, Figure 2) as well as higher rates of DGF (Fig 3), where RR and RF have previously proved unreliable.

Though exciting, the results of this study are limited by several factors, including its single-center nature and sample size. A larger, multi-center study would greatly improve demographic and practice diversity in addition to increasing the sample size. Furthermore, only 5 recipients demonstrated delayed graft function, limiting the clinical interpretation of our calculated specificity and sensitivity (Fig 3). Finally, though measures of early graft function were used as the primary outcomes, extension of the study period to longer than POD4 may

reveal additional insights. Ongoing investigations will address these limitations. Despite these limitations, our findings indicate that sDNA is a promising predictor of post-transplant function in human renal allografts undergoing HMP. Future work will be devoted to incorporating these findings into clinical practice.

In conclusion, we demonstrate that the concentration of sDNA in the perfusate of *ex vivo* hypothermic perfused kidney grafts provides insight on the quality of these grafts at the time of transplantation. Furthermore, the sDNA levels are directly correlated with early post-transplant renal function. We propose that perfusate sDNA should be explored as a candidate biomarker for tissue damage and early graft function in hypothermic machine perfused renal allografts.

#### Disclosures

The authors have nothing to disclose.

#### Funding

This study was supported by an ASTS-CareDx Career Development Grant and by NIH/NIDDK K08DK113244 (AZ).

### References

 Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009 Jan 1;360(1):7-19. doi: 10.1056/NEJMoa0802289. PMID: 19118301.

- Tingle SJ, Figueiredo RS, Moir JA, Goodfellow M, Talbot D, Wilson CH. Machine perfusion preservation versus static cold storage for deceased donor kidney transplantation. Cochrane Database Syst Rev. 2019 Mar 15;3(3):CD011671. doi: 10.1002/14651858.CD011671.pub2. PMID: 30875082; PMCID: PMC6419919.
- Korayem IM, Agopian VG, Lunsford KE, Gritsch HA, Veale JL, Lipshutz GS, et al.. Factors predicting kidney delayed graft function among recipients of simultaneous liverkidney transplantation: A single-center experience. Clin Transplant. 2019 Jun;33(6):e13569. doi: 10.1111/ctr.13569. Epub 2019 May 7. PMID: 31006141; PMCID: PMC6653637.
- Kruszyna T, Richter P. Hypothermic Machine Perfusion of Kidneys Compensates for Extended Storage Time: A Single Intervention With a Significant Impact. Transplant Proc. 2021 Apr;53(3):1085-1090. doi: 10.1016/j.transproceed.2021.01.022. Epub 2021 Feb 10. PMID: 33579549.
- Lam NN, Boyne DJ, Quinn RR, Austin PC, Hemmelgarn BR, Campbell P, et al. Mortality and Morbidity in Kidney Transplant Recipients With a Failing Graft: A Matched Cohort Study. Can J Kidney Health Dis. 2020 Apr 14;7:2054358120908677. doi: 10.1177/2054358120908677. PMID: 32313663; PMCID: PMC7158256.
- Henry ML, Sommer BG, Ferguson RM. Renal blood flow and intrarenal resistance predict immediate renal allograft function. Transplant Proc 1986; 18: 557.

- Sonnenday CJ, Cooper M, Kraus E, Gage F, Handley C, Montgomery RA. The hazards of basing acceptance of cadaveric renal allografts on pulsatile perfusion parameters alone. Transplantation. 2003 Jun 27;75(12):2029-33. doi: 10.1097/01.TP.0000065296.35395.FD. PMID: 12829906.
- Mozes MF, Skolek RB, Korf BC. Use of perfusion parameters in predicting outcomes of machine-preserved kidneys. Transplant Proc. 2005 Jan-Feb;37(1):350-1. doi: 10.1016/j.transproceed.2005.01.058. PMID: 15808640.
- Singh N, Logan A, Schenk A, Bumgardner G, Brock G, El-Hinnawi A, et al. Machine perfusion of kidney allografts affects early but not late graft function. Am J Surg. 2022 Apr;223(4):804-811. doi: 10.1016/j.amjsurg.2021.06.019. Epub 2021 Jul 6. PMID: 34253338; PMCID: PMC9017432.
- Hosgood SA, Barlow AD, Hunter JP, Nicholson ML. Ex vivo normothermic perfusion for quality assessment of marginal donor kidney transplants. Br J Surg. 2015 Oct;102(11):1433-40. doi: 10.1002/bjs.9894. Epub 2015 Aug 27. PMID: 26313559.
- Bellini MI, Tortorici F, Amabile MI, D'Andrea V. Assessing Kidney Graft Viability and Its Cells Metabolism during Machine Perfusion. Int J Mol Sci. 2021 Jan 23;22(3):1121. doi: 10.3390/ijms22031121. PMID: 33498732; PMCID: PMC7865666.

- De Beule J, Jochmans I. Kidney Perfusion as an Organ Quality Assessment Tool-Are We Counting Our Chickens Before They Have Hatched? J Clin Med. 2020 Mar 23;9(3):879. doi: 10.3390/jcm9030879. PMID: 32210197; PMCID: PMC7141526.
- 13. van Smaalen TC, Hoogland ER, van Heurn LW. Machine perfusion viability testing. Curr Opin Organ Transplant. 2013 Apr;18(2):168-73. doi: 10.1097/MOT.0b013e32835e2a1b.
  PMID: 23385886.
- 14. Guzzi F, Knight SR, Ploeg RJ, Hunter JP. A systematic review to identify whether perfusate biomarkers produced during hypothermic machine perfusion can predict graft outcomes in kidney transplantation. Transpl Int. 2020 Jun;33(6):590-602. doi: 10.1111/tri.13593. Epub 2020 Feb 28. PMID: 32031281.
- Parikh CR, Hall IE, Bhangoo RS, Ficek J, Abt PL, Thiessen-Philbrook H, et al. Associations of Perfusate Biomarkers and Pump Parameters With Delayed Graft Function and Deceased Donor Kidney Allograft Function. Am J Transplant. 2016 May;16(5):1526-39. doi: 10.1111/ajt.13655. Epub 2016 Feb 17. PMID: 26695524; PMCID: PMC4844819.
- 16. Kanou T, Nakahira K, Choi AM, Yeung JC, Cypel M, Liu M, et al. Cell-free DNA in human ex vivo lung perfusate as a potential biomarker to predict the risk of primary graft dysfunction in lung transplantation. J Thorac Cardiovasc Surg. 2021 Aug;162(2):490-499.e2. doi: 10.1016/j.jtcvs.2020.08.008. Epub 2020 Aug 11. PMID: 32928548.

- 17. Boominathan V, Willman M, Battula N, Zarrinpar A, Duarte S. Perfusate Cell-Free DNA Content is a Potential Marker of Cellular Injury During Hypothermic Machine Perfusion of Porcine Kidneys Subject to Prolonged Warm Ischemia [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/perfusate-cellfree-dna-content-is-a-potential-marker-of-cellular-injury-during-hypothermic-machineperfusion-of-porcine-kidneys-subject-to-prolonged-warm-ischemia/. Accessed November 17, 2022.
- 18. Sedigh A, Tufveson G, Bäckman L, Biglarnia AR, Lorant T. Initial experience with hypothermic machine perfusion of kidneys from deceased donors in the Uppsala region in Sweden. Transplant Proc. 2013 Apr;45(3):1168-71. doi: 10.1016/j.transproceed.2012.10.017. PMID: 23622652.
- Patel SK, Pankewycz OG, Nader ND, Zachariah M, Kohli R, Laftavi MR. Prognostic utility of hypothermic machine perfusion in deceased donor renal transplantation. Transplant Proc. 2012 Sep;44(7):2207-12. doi: 10.1016/j.transproceed.2012.07.129. PMID: 22974956.
- Zens TJ, Danobeitia JS, Leverson G, Chlebeck PJ, Zitur LJ, Redfield RR, et al. The impact of kidney donor profile index on delayed graft function and transplant outcomes: A single-center analysis. Clin Transplant. 2018 Mar;32(3):e13190. doi: 10.1111/ctr.13190. PMID: 29314286; PMCID: PMC6455919

- 21. Howard DH. Why do transplant surgeons turn down organs? A model of the accept/reject decision. J Health Econ. 2002 Nov;21(6):957-69. doi: 10.1016/s0167-6296(02)00077-2.
  PMID: 12475120.
- 22. Butt AN, Swaminathan R. Overview of circulating nucleic acids in plasma/serum. Ann NY Acad Sci. 2008 Aug;1137:236-42. doi: 10.1196/annals.1448.002. PMID: 18837954.
- Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids--a promising, noninvasive tool for early detection of several human diseases. FEBS Lett. 2007 Mar 6;581(5):795-9. doi: 10.1016/j.febslet.2007.01.051. Epub 2007 Feb 2. PMID: 17289032.
- Ranucci R. Cell-Free DNA: Applications in Different Diseases. Methods Mol Biol.
   2019;1909:3-12. doi: 10.1007/978-1-4939-8973-7\_1. PMID: 30580419.
- 25. Gielis EM, Ledeganck KJ, De Winter BY, Del Favero J, Bosmans JL, Claas FH, et al. Cell-Free DNA: An Upcoming Biomarker in Transplantation. Am J Transplant. 2015 Oct;15(10):2541-51. doi: 10.1111/ajt.13387. Epub 2015 Jul 16. PMID: 26184824.
- 26. Beck J, Oellerich M, Schulz U, Schauerte V, Reinhard L, Fuchs U, et al. Donor-Derived Cell-Free DNA Is a Novel Universal Biomarker for Allograft Rejection in Solid Organ Transplantation. Transplant Proc. 2015 Oct;47(8):2400-3. doi: 10.1016/j.transproceed.2015.08.035. PMID: 26518940.

- 27. Oellerich M, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, et al. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. Am J Transplant. 2019 Nov;19(11):3087-3099. doi: 10.1111/ajt.15416. Epub 2019 May 28. PMID: 31062511; PMCID: PMC6899936.
- Swanson KJ, Aziz F, Garg N, Mohamed M, Mandelbrot D, Djamali A, et al. Role of novel biomarkers in kidney transplantation. World J Transplant. 2020 Sep 18;10(9):230-255. doi: 10.5500/wjt.v10.i9.230. PMID: 32995319; PMCID: PMC7504189.
- 29. Govani MV, Kwon O, Batiuk TD, Milgrom ML, Filo RS. Creatinine reduction ratio and 24-hour creatinine excretion on posttransplant day two: simple and objective tools to define graft function. J Am Soc Nephrol. 2002 Jun;13(6):1645-9. doi: 10.1097/01.asn.0000014253.40506.f6. PMID: 12039994.
- 30. Rodrigo E, Ruiz JC, Piñera C, Fernández-Fresnedo G, Escallada R, Palomar R, et al. Creatinine reduction ratio on post-transplant day two as criterion in defining delayed graft function. Am J Transplant. 2004 Jul;4(7):1163-9. doi: 10.1111/j.1600-6143.2004.00488.x. PMID: 15196076.
- Vilar E, Varagunam M, Yaqoob MM, Raftery M, Thuraisingham R. Creatinine reduction ratio: a useful marker to identify medium and high-risk renal transplants. Transplantation. 2010 Jan 15;89(1):97-103. doi: 10.1097/TP.0b013e3181be3dd1. PMID: 20061925.

### Tables

**Table 1**. Donor and recipient demographics. Some donor kidney totals (n) do not add up to the total number of transplants performed (n=52), as this information was absent from the kidney donor information sheet at the time of data collection.

Recipients				
Age (years $\pm$ SD)	53 ± 15			
<b>Sex</b> n (%)				
Male	32 (61.5)			
Female	20 (38.5)			
Ethnicity n (%)				
Non-Hispanic White	25 (48.1)			
Hispanic	7 (13.5)			
Non-Hispanic Black	19 (36.5)			
Pacific Islander	1 (1.9)			
<b>BMI</b> (kg/m <sup>2</sup> $\pm$ SD)	$28.26 \pm 5.40$			
<b>Baseline Cr</b> (mg/dL $\pm$ SD)	$8.66 \pm 4.69$			
Preoperative eGFR (mL/min±SD)	9.94 ± 10.16			
Donors				
Age (years $\pm$ SD)	$39 \pm 15$			
Sex n (%)				
Male	31 (60.8)			
Female	20 (39.2)			
Ethnicity n (%)				
Non-Hispanic White	36 (70.6)			
Hispanic	10 (19.6)			
Non-Hispanic Black	5 (9.8)			
Allograft Laterality n (%)				
Left Kidney	27 (56.3)			
Right Kidney	21 (43.7)			
<b>KDPI</b> (% $\pm$ SD)	$45.5 \pm 27$			
Type of Donation n (%)				
Donation after Brain Death	37 (75.5)			
Donor after Circulatory Death	12 (24.5)			
<b>Mean Ischemia Time</b> (min ± SD)	$640 \pm 309$			
Mean HMP Time (min±SD)	$477 \pm 256$			
<b>Mean Cold Ischemia Time</b> (min ± SD)	$1127\pm405$			

SD: standard deviation; BMI: body mass index; KDPI: kidney donor profile index; HMP: hypothermic machine perfusion.

Table 2. sDNA levels and ex vivo organ timepoints.

sDNA Concentration (ng/ml) vs Ischemic Parameters				
Timepoint	Variable	Spearman Correlation (ρ)	p-value	
	Static Ice Time	0.0287	0.847	
5 min	HMPT	0.149	0.313	
	CIT	0.1486	0.313	
	Static Ice Time	0.0877	0.5404	
Handoff	HMPT	0.238	0.0928	
	CIT	0.3049	0.0296	

HMPT: hypothermic machine perfusion time; CIT: cold ischemia time (CIT).

Endpoint Renal Flow					
Timepoint	<b>Outcome Variable</b>	Spearman Correlation (ρ)	p-value		
POD 1	Cr	-0.166	0.234		
	eGFR	0.212	0.128		
	CRR	-0.157	0.263		
	Cr	-0.097	0.486		
POD 2	eGFR	0.091	0.515		
	CRR	-0.119	0.398		
	Cr	-0.020	0.890		
POD 3	eGFR	0.007	0.959		
	CRR	-0.181	0.199		
	Cr	-0.137	0.393		
POD 4	eGFR	0.210	0.183		
	CRR	-0.106	0.511		
Endpoint Renal Resistance					
Timepoint	<b>Outcome Variable</b>	Spearman Correlation (ρ)	p-value		
	Cr	0.309	0.027		
POD 1	eGFR	-0.256	0.069		
	CRR	0.091	0.525		
	Cr	0.302	0.031		
POD 2	eGFR	-0.293	0.037		
	CRR	0.075	0.598		
	Cr	0.216	0.140		
POD 3	eGFR	-0.233	0.099		
	CRR	0.112	0.441		
	Cr	0.122	0.455		
POD 4	eGFR	-0.182	0.260		
	CRR	0.229	0.161		
		KDPI (%)			
Timepoint	<b>Outcome Variable</b>	Spearman Correlation (ρ)	p-value		
<u>R</u>	Cr	0.307	0.028		
POD 1	eGFR	-0.286	0.042		
	CRR	-0.160	0.262		
	Cr	0.379	0.0061		
POD 2	eGFR	-0.394	0.0042		
	CRR	-0.198	0.164		
POD 3	Cr	0.377	0.0069		
	eGFR	-0.392	0.0045		
	CRR	-0.161	0.265		
	Cr	0.418	0.0082		
POD 4	eGFR	-0.395	0.012		
	CRR	-0.145	0.377		

**Table 3.** Comparing post-transplant outcomes with renal flow, renal resistance, and kidney donor profile index.

HMP: hypothermic machine perfusion; POD: postoperative day; KDPI: kidney donor profile index; Cr: Creatinine; eGFR: estimated glomerular filtration rate; CRR: creatinine reduction ratio.

Timepoint	<b>Outcome Variable</b>	Spearman Correlation (ρ)	p-value
	Cr	0.041	0.774
POD 1	eGFR	-0.107	0.457
	CRR	-0.390	0.0043
	Cr	0.214	0.131
POD 2	eGFR	-0.256	0.069
	CRR	-0.351	0.0107
	Cr	0.382	0.006
POD 3	eGFR	-0.367	0.0088
	CRR	-0.485	0.0003
POD 4	Cr	0.330	0.043
	eGFR	-0.373	0.019
	CRR	-0.500	0.0012

### **Table 4.** Handoff sDNA concentration correlation with early graft function.

POD: postoperative day; Cr: creatinine; eGFR: estimated glomerular filtration rate; CRR: creatinine reduction ratio.

## **Figure Legends**

**Figure 1. Study Methods.** The perfusate of human kidneys undergoing hypothermic machine perfusion was sampled, and soluble DNA (sDNA) was extracted and quantified. After the kidney was transplanted into the recipient, post-transplant outcomes and measures of kidney function were assessed.

**Figure 2. Handoff sDNA vs measurements of early graft function.** Handoff sDNA negatively correlated with creatinine reduction ratio (CRR) on all postoperative days (POD) (A-D). Handoff sDNA showed a similar negative correlation with estimated glomerular filtration rate (eGFR) on POD3 (E) and POD4 (not shown), as well as a positive correlation with POD3 (F) and POD4 Creatinine.

Figure 3. Soluble DNA levels in predicting delayed graft function (DGF). Handoff (A) and 5min (B) sDNA concentration was significantly higher in the five individuals who exhibited DGF. The receiver operating characteristic (ROC) curves for our cohort demonstrate that sDNA as a biomarker for DGF has a reliable prognostic performance with an area under curve (AUC) of 0.816 for samples obtained at handoff (C) and AUC=0.771 for samples obtained at 5min perfusion (D). Conversely, the ROC curves for Kidney Donor Profile Index (KDPI, E), renal vascular flow (F), and renal vascular resistance (G) were less reliable and were not statistically significant (KDPI AUC=0.748, p=0.074; flow AUC=0.600, p=0.485; resistance AUC=0.633, p=0.330)





